Telbivudine induced vomiting with elevated creatine kinase and lactic acid: a case report

doi:10.19803/j.1672-8629.2021.12.25

Abstract

Abstract: Objective To analyze a case of vomiting with elevated creatine kinase and lactic acid caused by tibivudine, so as to provide reference for clinical safe drug use. Methods The process of treating one case of vomiting with elevated creatine kinase and lactic acid caused by tibivudine was analyzed based on literature retrieval. Results The patient appeared recurrent vomiting, creatine kinase 1 559 U·L^-1 and blood lactic acid 8.930 mmol·L^-1 after using tibivudine about 5 months. Stopped using tibivudine immediately and changed to entecavir. The patient was getting better. 2 weeks after withdrawal, there were no vomiting symptoms, creatine kinase and blood lactic acid basically returned to normal. Conclusion We should pay close attention to the occurrence of adverse reactions when using tibivudine. Once vomiting, elevated creatine kinase and lactate increase occur, the drug should be stopped in time and changed the treatment plan.

Key words: telbivudine, adverse drug reaction, emesis, hyperlactic acidemia, creatine kinase elevated

CLC Number:

R994.11

LIANG Kai, LAI Mingyu. Telbivudine induced vomiting with elevated creatine kinase and lactic acid: a case report[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 111-112.

References

[1] MONDELLI M.New treatment options in chronic hepatitis B[J]. Infez Med, 2008, 16(1): 5-14.
[2] JIN H, ZHOU ZY, WANG CX, et al.Analysis of serious adverse reactions induced by tibivudine[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2018, 35(8): 1245-1247.
[3] WANG Y, THONGSAWAT S, GANE EJ, et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J]. J Viral Hepat, 2013, 20(4): e37-e46.
[4] YI ZM, LIU F, PEI ZE, et al.Myopathy and peripheral neuropathy caused by telbivudine: analysis of 27 reports of serious adverse reactions[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2012, 14(6): 352-355.
[5] LIU M, YI W, CAI HD.Myositis and peripheral neuropathy associated with telbivudine and interferon[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2010, 12(2): 130-131.
[6] JIN JL, HU P, LU JH, et al.Lactic acidosis during telbivudine treatment for HBV: a case report and literature review[J]. World J Gastroenterol, 2013, 19(33): 5575-5580.
[7] HUANG F, WANG SM, DONG Y, et al.A case of tibivudine induced creatine kinase elevation with vomiting[J]. Chinese Hepatology(肝脏), 2018, 23(7): 655-656.
[8] SHE CS, DENG YL.A case of telbivudine-related fatal lactic acidosis and multiple organ dysfunction syndrome[J]. Journal of Central South University(Medical Science)[中南大学学报(医学版)] , 2019, 44(6): 714-719.
[9] ZHU RY, LU SW, TENG YL.A case of tibivudine resulted in death by rhabdomyolysis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2010, 7(5): 309-310.
[10] LIU MX, SONG J, ZHANG CH, et al.One case of peripheral neuropathy induced by telbivudine tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(6): 381-382.
[11] LIAW YF, GANE E, LEUNG N, et al.2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology, 2009, 136(2): 486-495.
[12] ZHANG XS, JIN R, ZHANG SB, et al.Clinical features of adverse reactions associated with telbivudine[J]. World J Gastroenterol, 2008, 14(22): 3549-3553.
[13] Chinese Society of Infectious Diseases, Chinese Society of Hepatology. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019 )[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2019, 35(12): 2648-2669.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.